Sign in to view content

Comparison of CRISPR-based Genome Editing of VEGF-A as Treatment Strategy for Choroidal Neovascularization

Glenn C. Yiu, MD, PhD

Video
Published 2019

Related

A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018
Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Optimization of the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure in the LADDER Phase 2 Trial
Mark R. Wieland, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more